OTCM
BNKL
Market cap1kUSD
May 27, Last price
0.00USD
Name
Bionik Laboratories Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bionik Laboratories Corp. operates as a robotics firm, focusing on the innovation, development, and market introduction of advanced solutions for physical rehabilitation, prosthetic devices, and assistive robotics. The company's product range features the InMotion Robots, a comprehensive collection of robotic therapy tools. This includes the InMotion ARM, an intelligent and interactive therapeutic system grounded in scientific evidence, adept at perceiving patient movements and physical restrictions. Additionally, the InMotion ARM/HAND is offered to facilitate therapies requiring reaching with grasping and releasing actions, alongside individual hand manipulations. Rounding out their offerings is the InMotion Connect platform, which integrates a hardware unit that interfaces with an InMotion Robot, coupled with a subscription for the InMotion Connect Pulse service. Established in 2010, Bionik Laboratories Corp. maintains its principal operations in Watertown, Massachusetts.
Key people
Eric Michel Dusseux
Chief Executive Officer, Director · since 2017
Chief Financial Officer · since 2017
Malcolm G. Bock
Vice President - Engineering · since 2017
Bill Harris
Director - Marketing · since 2017
Loren W. Wass
Chief Commercial Officer · since 2019
Andre-Jacques Auberton-Herve
Chairman of the Board · since 2018
Remi Gaston Dreyfus
Independent Director · since 2017
Independent Director · since 2018
Independent Director
Charles Matine
Independent Director · since 2018
Audrey Thevenon
Independent Director · since 2018
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
167 Penn Street
Washington Boro
Manor Township, PA 17582
US
Washington Boro
Manor Township, PA 17582
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||